



BioCryst to Present at Upcoming Investor Conference

July 15, 2022

RESEARCH TRIANGLE PARK, N.C., July 15, 2022 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](http://www.biocryst.com) (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 1st Annual Hereditary Angioedema Virtual Conference on Wednesday, July 20, 2022, at 10:00 a.m. ET.

The link to a live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at <http://www.biocryst.com>.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and multiple global markets. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and yellow fever. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company's website at www.biocryst.com.

BCRXW

Investor Contact:

John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:

Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com